SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
TSHA reported Third quarter ended September 30, 2026 results. The stock moved -1.6% on the print.
TSHAearnings

Earnings reactions, page 3

Taysha Gene Therapies, Inc. (TSHA) Q3 FY2026 earnings

November 12, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $28.8 million for the three months ended September 30, 2026 (GAAP).
  • General and administrative expenses were $13.1 million for the three months ended September 30, 2026 (GAAP).
  • Net loss was $39.1 million, or $0.10 per share, for the three months ended September 30, 2026 (GAAP).
  • Cash and cash equivalents were $422.8 million as of September 30, 2026 (GAAP).

Guidance

  • Expect to report topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.
  • Expect FDA feedback following CMC Type B meeting in the first quarter of 2027.
  • Expect to nominate an additional gene therapy development candidate and commence preclinical development activities in the first half of 2027.
  • Expect that current cash resources will support planned operating expenses and capital requirements into the second half of 2028.

Price and volatility reaction

The stock moved -1.6% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release4.282026-11-11
Close after release4.212026-11-12
Realised move-1.6%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →